Drug Trial Radar · NCT06144723
Study of HS-20105 for Injection in Patients With Advanced Solid Tumors.
Last checked: Nov 19, 2026Latest source record: Nov 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
402
Planned (sponsor's estimate)
Start
Mar 1, 2024
Primary completion
Mar 2026
Study completion Mar 1, 2027
Sponsor
- Lead sponsor
- Hansoh BioMedical R&D CompanyIndustry
- Sponsor type
- Industry
- First posted
- Nov 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
HS-20105 is a novel antibody-drug conjugate (ADC) targeting Trop-2. This first-in-human trial is aimed to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics (PK), safety and preliminary anti-tumor activity of HS-20105 in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
HS-20105Drug
Administered intravenously every 21 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ia: MTD or maximum applicable dose (MAD) of HS-20105Time frame: Up to12 months.
- Phase Ib: Efficacy of HS-20105Time frame: Up to 24 months.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.